Bioresorbable Scaffolds Versus Metallic Drug-Eluting Stents Are We Getting Any Closer to a Paradigm Shift?∗ by Windecker, Stephan et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 6 , N O . 2 1 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 1 0 . 0 0 2EDITORIAL COMMENTBioresorbable Scaffolds Versus
Metallic Drug-Eluting Stents
Are We Getting Any Closer to a Paradigm Shift?*Stephan Windecker, MD, Konstantinos C. Koskinas, MD, George C.M. Siontis, MDS ince the ﬁrst catheter-based coronary treat-ment in 1977, interventional cardiology haswitnessed several practice-changing paradigm
shifts. The transition from balloon angioplasty to
bare-metal stents to drug-eluting stents (DES) sub-
stantially advanced the safety and efﬁcacy of percuta-
neous coronary interventions (PCI) and improved
patient outcomes (1). Bioresorbable vascular scaffolds
(BVS) have emerged as a promising new link in this
chain of major breakthroughs in intracoronary device
technology. BVS provide temporary vessel support,
retain the ability of antirestenotic drug elution, and
dissolve within a well-deﬁned time frame. Due to
this principle function, BVS may provide therapeutic
features that could extend well beyond current
metallic DES by enabling positive vessel remodeling
and late lumen gain (2), enhancing the process of
long-term arterial healing (3), entailing plaque shield-
ing properties (4), and restoring physiological vaso-
motion (5). In aggregate, these properties bear the
potential to further advance clinical outcomes
including the ability to reduce angina symptoms
compared with metallic stents (6).
The conformability and superior ﬂexibility of
BVS allows for minimal changes of vessel geometry
and along with the eventual absorption of the
lumen-protruding struts attenuate the unfavorable*Editorials published in the Journal of the American College of Cardiology
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contents of this paper to disclose.hemodynamic changes that are typically imposed by
rigid stents (7). Elimination of late-acquired malap-
position (an established trigger of stent thrombosis)
or edge-related vascular responses in the long term
are additional theoretical beneﬁts of BVS. On the
other hand, strut thickness is larger compared with
new-generation DES, which leads to suboptimal
crossing proﬁles, limits the ability to treat complex
(e.g., excessively tortuous or calciﬁed) lesions or
to implant overlapping BVS, and results in inferior
immediate, post-procedural angiographic outcomes
of device performance (6).
A variety of BVS is currently under investigation,
and both polymer-based as well as metal (magne-
sium)-based BVS with drug-eluting properties have
entered clinical investigations (8). The everolimus-
eluting Absorb BVS is the most widely used and
investigated device to date. The initial ABSORB
Cohort A and B studies (ABSORB A and ABSORB B)
demonstrated the feasibility of the BVS in highly
selected patients with simple lesions (9). Real-world
observations (10–13) and, more recently, randomized
trials (3,6,14,15) have gone a step further by
comparing the performance of the BVS with new-
generation DES. Against this background, 1-year
angiographic and clinical results of the ABSORBSEE PAGE 2298China trial are reported in this issue of the Journal (16).
The trial, designed to enable regulatory approval
of the device in China, randomized 480 patients
with up to 2 de novo lesions in a 1:1 fashion to
Absorb BVS or the metallic everolimus-eluting Xience
stent platform. The study was able to show non-
inferiority of the BVS versus Xience for the primary
angiographic endpoint, in-segment late lumen loss at
12 months (0.19  0.38 vs. 0.13  0.37, p for
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2311noninferiority ¼ 0.01). Of note, minimal lumen diam-
eter was smaller (2.27  0.03 mm vs. 2.50  0.03 mm;
p < 0.001), and % diameter stenosis was greater
(18.5  0.92% vs. 11.3  0.76%; p < 0.001) for the BVS
within the device, whereas in-segment measures did
not differ. Clinical outcomes, including target-lesion
failure and stent thrombosis, were similarly low
between the 2 groups, although the study was not
powered for any individual or composite clinical
endpoint (16). The open-label design in contrast to
the single-blind design of previous randomized trials
of BVS versus DES (3,6,14,15) also needs to be taken
into account.
The ABSORB China trial is a valuable contribution
to the growing body of evidence comparing the
angiographic and clinical performance of BVS versus
the current standard-of-care for PCI, that is, new-
generation DES (17). The ﬁndings are in line with
recent randomized trials (3,6,14,15) indicating non-
inferiority of angiographic efﬁcacy and comparably
low mid-term rates of device-oriented as well as
patient-oriented clinical events. The concordance of
ﬁndings across different ethnicities corroborates their
generalizability, and the consistency in a ST-segment
elevation myocardial infarction cohort (3) extends the
disease-speciﬁc indications of the device to patients
with higher-risk clinical presentation. Notably, how-
ever, the ﬁndings remain applicable to relatively
noncomplex anatomies because bifurcation and
calciﬁed lesions were underrepresented, and left
main lesions and multivessel treatment were
excluded from these trials.
With a handful of randomized comparisons of
BVS versus metallic DES, including >1,800 patients,
now available, our ability has grown to draw a more
complete picture of this technology both in terms of
mid-term angiographic efﬁcacy as well as clinical
performance. Because interpretation of ﬁndings is
limited by the modest sample size of individual
studies, a synthesis of the available evidence
by performing a meta-analysis of 5 trials (ABSORB II
[6]; ABSORB China [16]; ABSORB JAPAN [14];
EVERBIO II [Comparison of Everolimus- and
Biolimus-Eluting Stents With Everolimus-Eluting
Bioresorbable Vascular Scaffold Stents] [15]; and
ABSORB STEMI-TROFI II [ABSORB STEMI: the
TROFI II Study] [3] trials) focusing on angiographic
and clinical endpoints that are comparable across
the trials provides further insights. Statistical
methods for this meta-analysis are presented in the
Online Appendix. When addressing angiographic
efﬁcacy by using the primary endpoint of in-
segment late lumen loss, BVS is associated with
signiﬁcantly greater late lumen loss than metallicDES (0.05 mm; 95% conﬁdence interval [CI]: 0.01 to
0.09) (Figure 1). Risks of the device-oriented com-
posite endpoint target lesion failure (odds ratio
[OR]: 1.15; 95% CI: 0.71 to 1.85), the patient-oriented
composite endpoint of death, myocardial infarction,
or any revascularization (OR: 0.93; 95% CI: 0.67 to
1.30), and deﬁnite or probable stent thrombosis (OR:
1.86; 95% CI: 0.55 to 6.27) do not differ between BVS
and metallic DES throughout the observed period of
follow-up. Of note, there was no signiﬁcant heteroge-
neity across trials for the analyzed outcomes.
Collectively, individual randomized trials have
demonstrated noninferior angiographic efﬁcacy re-
sults for the BVS compared with metallic DES (i.e., the
Xience stent in all but 1 trial [15]); however, a signif-
icant difference of late lumen loss in favor of DES
emerged in the present meta-analysis. This ﬁnding
may need to be interpreted in light of the low re-
ported rates of periprocedural intracoronary imaging
in some of the trials (15,16). Given the importance
of accurate size estimation and the limitations in
terms of aggressive post-dilation techniques (due to
the risk of polymeric stent disruption in case of
excessive overexpansion), intracoronary imaging—in
particular optical coherence tomography—to guide
and optimize BVS implantation may assume a prom-
inent role for improving post-procedural and pre-
sumably longer-term angiographic outcomes (18),
although this requires conﬁrmation in appropriately
designed studies.
Whereas angiographic measures of device efﬁcacy
are essential, the clinical relevance of these differ-
ences needs to be placed in a broader perspective.
The penetration of bioresorbable stents in routine
interventional practice within the next years will be
determined largely by their impact on patient out-
comes. At present, both randomized and observa-
tional evidence (10–13) suggests comparable device
efﬁcacy and similarly low event rates, as conﬁrmed
also in the pooled analysis presented here. Although
it becomes increasingly challenging for new intra-
coronary devices to achieve meaningful improve-
ments against the current standard-of-care, clinical
studies with larger and more complex populations
and longer follow-up durations (extending to the
time frame before, as well as after complete scaffold
resorption) are critical to deﬁnitively establish at least
the non-inferiority of the BVS (and of other BVS
currently under development) versus the best avail-
able metallic DES. In this respect, long-term outcomes
of ABSORB II, the ongoing ABSORB III (ABSORB III
Randomized Controlled Trial; NCT01751906 and
ABSORB IV trials (ABSORB IV Randomized Controlled
Trial; NCT02173379) with 5,000 patients, and the
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(A) Characteristics of randomized trials comparing bioresorbable vascular scaffolds (BVS) versus metallic drug-eluting stents (DES). (B) Meta-analysis
of BVS versus metallic DES for in-segment late lumen loss in randomized trials with reported angiographic follow-up. Each study is presented by name
with point estimate of mean difference and respective 95% conﬁdence intervals (CI). (C) Meta-analysis of BVS versus metallic DES for stent thrombosis
(deﬁnite or probable); the device-oriented composite endpoint target-lesion failure (cardiac death, target-vessel myocardial infarction [MI], or ischemia-
driven target lesion revascularization); and the patient-oriented composite endpoint of death, MI, or any revascularization at follow-up. Each study is
presented by name with point estimate of odds ratio (OR) and respective 95% CIs. The overall mean difference (B) and overall OR (C) and the respective
95% CIs are shown according to a random-effects model (REM) and a ﬁxed-effects model (FEM), with studies weighted by the inverse of their variance.
Follow-up is shown in months. The EVERBIO trial is not included in the analysis of stent thrombosis due to zero events in both intervention arms. MACE ¼
major adverse cardiac events; OCT ¼ optical coherence tomography.
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2312AIDA trial (Amsterdam Investigator-initiateD Absorb
Strategy All-comers Trial; NCT01858077) with 2,690
patients and 5-year follow-up will critically expand
current evidence and inform our practice.
Rates of BVS versus metallic DES thrombosis were
similar in all individual trials during a 6- to 12-month
follow-up (3,6,14–16) and did not differ when >1,500
patients were pooled (Figure 1C); notably, pointestimates indicate a 74% numerically higher risk of
BVS versus metallic stent thrombosis. Along the
same lines, observational studies that included
relatively more complex patient and lesion subsets
have demonstrated 6 to 12 months deﬁnite/probable
BVS thrombosis rates up to 3% in general pop-
ulations (12) and up to 2.4% in ST-segment elevation
myocardial infarction patients (11), with consistent
FIGURE 1 Continued
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2313numerical (albeit not statistically signiﬁcant) pre-
ponderance over DES. These ﬁgures have raised
some concerns and need to be viewed also in
conjunction with evidence of very late (up to 44
months) thrombosis related to scaffold discontinuity
or restenosis during advanced stages of the resorp-
tion process, which may be more delayed in human
compared with experimental (porcine) models (19).
Adequately powered randomized trial data with
prolonged follow-up as those mentioned above will
provide the answer whether these concerns can be
alleviated to more deﬁnitely conﬁrm the safety of
the BVS versus new-generation DES.
Summarizing the facts and ﬁction of the Absorb
BVS, the theoretical advantages of “uncaging” the
treated vessel are substantial, yet the BVS (and other
emerging device technologies) somehow pay the
price of current standards being extraordinarily highwith new-generation DES. At present, evidence on the
performance of the BVS versus contemporary DES
does indicate clinical noninferiority—the Hippocratic
analogue of primum non nocere (“ﬁrst, do no harm”)
in the randomized trials world. This needs to be
further corroborated and carefully weighed against
concerns regarding thrombotic complications in
larger, broadly inclusive, longer-term studies, also
addressing issues of cost-effectiveness and optimal
adjunctive antiplatelet regimens. Within the time
frame needed for a BVS that is implanted today to be
fully absorbed, we should be able to answer these
questions.
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